Knight Therapeutics Inc. (GUD.TO)

5,87 -0,05 (-0,84%) Börsenschluss: 04:00PM EDT

Knight Therapeutics Inc.

3400 de Maisonneuve Boulevard West
Suite 1055
Montreal, QC H3Z 3B8
Canada
514-484-4483
https://www.gud-knight.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 725

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.	Executive Chairman	250,94k	N/A	1969
Ms. Samira Sakhia BCom, CA, CPA, MBA	President, CEO & Director	674,28k	N/A	1968
Mr. Arvind Utchanah	Chief Financial Officer	607,22k	N/A	N/A
Ms. Amal Khouri B.Sc., M.B.A.	Chief Business Officer	519,87k	N/A	N/A
Mr. Jeff Martens	Global Vice President of Commercial	420,4k	N/A	N/A
Mr. Stephani Saverio	Vice President of Business Development	440,65k	N/A	N/A
Mr. Leopoldo Bosano	Vice-President of Manufacturing & Operations	N/A	N/A	N/A
Ms. Monica Percario	Global Vice President of Scientific Affairs	N/A	N/A	N/A
Mr. Henrique Dias	Global Director of Marketing	N/A	N/A	N/A
Ms. Susan Caroline Emblem	Global Vice President of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Corporate Governance

Knight Therapeutics Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 4, Vorstand: 5, Shareholderrechte: 8, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.